Close Menu

Becton Dickinson

In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.

The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.

The Cobas HPV Test is now approved for use as a primary screening test with BD's SurePath and Hologic's ThinPrep PreservCyt Solution.

Angle this week announced its preliminary financial results for the fiscal year ended April 30.

Agilent Technologies announced this week that it has agreed to acquire privately-held ProZyme, a provider of glycan analysis reagents, kits, and standards.

BioGx now offers 11 CE-marked infectious disease tests that run on Becton Dickinson's BD Max platform.

The firm has made two separate senior notes offerings in euros and British pounds, and it plans to use the proceeds to redeem other outstanding notes.

The firm raised its full fiscal year 2018 revenue and adjusted earnings per share guidance.

Enzo Biochem and its subsidiary Enzo Life Sciences announced this week that the Patent Trial and Appeal Board has denied a petition filed by Hologic for inter partes review, a procedure for challenging the validity of patent claims, against US Patent 6,221,581.

The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.

Pages